NL-OMON20151尚未招募不适用
A randomized, double blind, placebo-controlled, 2-way cross-over study to investigate the effects of inhaled THC on resting state functional magnetic resonance imaging in healthy volunteers.
CHDR in cooperation with LUMC0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 12
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Subject is a legally competent Caucasian male/female from 18 up to and including 45 years old (extremes included) on the day the informed consent is signed.
- •2.Subject is right-handed.
排除标准
- •1.Subject has a BMI below 18 or above 28.5 kg/m2.
- •2.Subject has a significant history of any cardiac or vascular disorder, asthma or other pulmonary disease, major gastrointestinal abnormalities, peptic ulceration, hepatic, neurological, psychiatric, haematological (including bleeding disorders), endocrine, renal, or major genitourinary disease or uses any kind of concomitant medication that - in the opinion of the investigator - may interfere with the study.
研究者
相似试验
进行中（未招募）
不适用
A randomized, double blind, placebo-controlled, 2-period cross over study to evaluate effects of S-555739 on prostaglandin D2 (PGD2) induced nasal airway resistance in healthy adult volunteersAllergic rhinitisMedDRA version: 9.1Level: LLTClassification code 10001723Term: Allergic rhinitisEUCTR2008-006787-11-GBShionogi & Co., Ltd.
已完成
不适用
A randomized, double blind, placebo-controlled, 2-way cross-over study to investigate the effects of inhaled THC on resting state functional magnetic resonance imaging in healthy volunteersNL-OMON32445Centre for Human Drug Research12
进行中（未招募）
1 期
A clinical study comparing efficacy and safety of xevinapant against placebo when given with radiotherapy in participants who had their locally advanced squamous cell carcinoma of the head and neck removed by surgery, are at high risk for the cancer to return and who cannot be treated with high-dose cisplatin.Resected squamous cell carcinoma of the head and neckMedDRA version: 21.0Level: PTClassification code 10060121Term: Squamous cell carcinoma of head and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001144-18-NLMerck Healthcare KGaA700
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pioglitazone in patients with type 2 diabetes not adequately controlled with pioglitazone. - GETGOAL-PType II diabetesMedDRA version: 10.1Level: LLTClassification code 10067585Term: <Manually entered code. Term in E.1.1>EUCTR2007-005884-92-ATSanofi-Aventis Recherche & Développement450
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in patients with type 2 diabetes not adequately controlled with sulfonylurea - GETGOAL-SEUCTR2007-005881-11-CZSanofi-Aventis Recherche&Développement855